Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H28O5 |
Molecular Weight | 360.444 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
Molecular Formula | C21H28O5 |
Molecular Weight | 360.444 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdfhttps://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA1012&lpg=PA1012&dq=prednazate+prednisolone&source=bl&ots=6IVjr7YAxt&sig=n3FMmropI-ytuQms6m0VusBrXNc&hl=ru&sa=X&ved=0ahUKEwilpZPbib7PAhXMESwKHZaaB18Q6AEIOzAE#v=onepage&q=prednazate%20prednisolone&f=false Retrieved from Dictionary of drugs: Chemical data, structures and bibliographies, edited by J. Elks and C. R. Ganellin, p.1012https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pilhttps://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html | https://humanpara.org/prednisone-and-prednisolone/ | https://www.drugbank.ca/drugs/DB00860Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3580023
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017469s040lbl.pdfhttps://books.google.ru/books?id=0vXTBwAAQBAJ&pg=PA1012&lpg=PA1012&dq=prednazate+prednisolone&source=bl&ots=6IVjr7YAxt&sig=n3FMmropI-ytuQms6m0VusBrXNc&hl=ru&sa=X&ved=0ahUKEwilpZPbib7PAhXMESwKHZaaB18Q6AEIOzAE#v=onepage&q=prednazate%20prednisolone&f=false Retrieved from Dictionary of drugs: Chemical data, structures and bibliographies, edited by J. Elks and C. R. Ganellin, p.1012https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pilhttps://www.drugs.com/pro/prednisolone-sodium-phosphate-oral-solution.html | https://humanpara.org/prednisone-and-prednisolone/ | https://www.drugbank.ca/drugs/DB00860
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3580023
Prednisolone is a synthetic adrenocortical steroid drug with predominantly glucocorticoid properties. Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones’ normal functions; they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of prednisolone which are due to its glucocorticoid properties include: promotion of gluconeogenesis; increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis; stimulation of fat synthesis and storage; increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion. Prednisolone is used to treat certain types of allergies, inflammatory conditions, autoimmune disorders, and cancers. Some of these conditions include adrenocortical insufficiency, high blood calcium, rheumatoid arthritis, dermatitis, eye inflammation, asthma, and multiple sclerosis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24347992https://medikamio.com/de-de/medikamente/prednisolut-1000-mg/pilhttps://www.ncbi.nlm.nih.gov/pubmed/11254764
Curator's Comment: oral prednisolone crosses the blood-brain barrier
Originator
Sources: http://www.novete.com/Corticoid/Prednisone.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/13371916http://www.worldcat.org/title/the-secret-of-success-arthur-nobiles-discovery-of-the-steroids-prednisone-and-prednisolone-in-the-1950s-revolutionised-the-treatment-of-arthritis/oclc/106716069&referer=brief_results | https://humanpara.org/prednisone-and-prednisolone/
Curator's Comment: # Merck and Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 |
5.7 nM [EC50] | ||
Target ID: CHEMBL2034 Sources: http://dictionary.sensagent.com/prednisone/en-en/ |
|||
Target ID: CHEMBL2034 Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D08413 |
|||
Target ID: CHEMBL2034 |
2.4 nM [Ki] | ||
Target ID: map07225 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D02156 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Primary | Prednisolone Approved UsePrednisolone Sodium Phosphate Oral Solution (10 mg Prednisolone per 5 mL) is indicated in the following conditions:
1. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions.
2. Dermatologic Diseases
Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides.
3. Edematous States
To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.
4. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.
5. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.
6. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.
7. Neoplastic Diseases
For the treatment of acute leukemia and aggressive lymphomas in adults and children.
8. Nervous System
Acute exacerbations of multiple sclerosis.
9. Ophthalmic Diseases
Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.
10. Respiratory Diseases
Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.
11. Rheumatic Disorders
As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychondritis, and certain cases of vasculitis.
12. Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). Launch Date1955 |
|||
Palliative | Sixtysix-20 Approved UseAntiinflammatory agent |
|||
Primary | OMNIPRED Approved UseSteroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date1973 |
|||
Primary | OMNIPRED Approved UseSteroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date1973 |
|||
Primary | OMNIPRED Approved UseSteroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date1973 |
|||
Primary | OMNIPRED Approved UseSteroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date1973 |
|||
Primary | OMNIPRED Approved UseSteroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Launch Date1973 |
|||
Curative | Prednisolut Approved UsePrednisolut is indicated in shock and emergency medicine: Shock due to a severe allergic reaction (anaphylactic shock), after previous treatment with epinephrine, progressive forms of allergic reactions in insect bites and snake bites |
|||
Primary | Prednisolut Approved UseBrain swelling (brain edema), triggered by brain tumor, neurosurgery, brain abscess, bacterial meningitis (meningitis). |
|||
Primary | Prednisolut Approved UsePrednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown. |
|||
Primary | Prednisolut Approved UsePrednisolut is indicated to treat acute asthma attack, pulmonary edema by inhalation of toxic substances such as chlorga's, isocyanates, hydrogen sulphide, phosgene, nitrose gas, ozone, also nitrogen oxide, by gastric juice aspiration, and by drown. |
|||
Primary | Prednisolut Approved UsePrednisolut is indicated for treatment of severe / life-threatening situations in the following rheumatic diseases: rheumatoid arthritis and still syndrome, felty syndrome, polymyalgia rheumatica, systemic juvenile idiopathic arthritis (eg breast disease, seropositive polyarthritis), collagenoses, vasculitides, rheumatic fever. |
PubMed
Title | Date | PubMed |
---|---|---|
Intravenous hydrocortisone hemisuccinate and prednisolone hemisuccinate. | 1956 Dec |
|
[Pharmacokinetics and pharmacodynamics of prednisolone following extremely high dosage as prednisolone hemisuccinate]. | 1987 Feb |
|
In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. | 1987 Sep |
|
Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. | 1988 Nov |
|
Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone. | 1993 |
|
Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid. | 1999 Jan |
|
Inhibition of calcineurin activity and protection against cyclosporine A induced cytotoxicity by prednisolone sodium succinate in human peripheral mononuclear cells. | 2000 Jun |
|
Comparison of suppressive potency between prednisolone and prednisolone sodium succinate against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro. | 2001 May |
|
Effects of octreotide acetate and amniotic membrane on wound healing in experimental glaucoma surgery. | 2003 Sep |
|
[Acceptability and tolerance of prednisolone metasulfobenzoate in orally dispersing tablets in 2 to 12-years-old children]. | 2004 Sep |
|
Effects of prednisolone on the systemic release of mediators of cell-mediated cytotoxicity during human endotoxemia. | 2008 Apr |
|
Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. | 2008 Feb 1 |
|
Protective effect of selected calcium channel blockers and prednisolone, a phospholipase-A2 inhibitor, against gentamicin and carbon tetrachloride-induced nephrotoxicity. | 2014 Aug |
|
The steroids for corneal ulcers trial (SCUT): secondary 12-month clinical outcomes of a randomized controlled trial. | 2014 Feb |
|
Preparation, characterization and evaluation of novel elastic nano-sized niosomes (ethoniosomes) for ocular delivery of prednisolone. | 2014 Sep |
Sample Use Guides
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6330758
Human polymorphonuclear leukocytes (PMNLs) were incubated for 60 min with 20 microM or 100 microM prednisolone, and stimulated thereafter for 1 min with 10 nM leukotriene B4 (LTB4), 10 nM leukotriene C4 (LTC4), 10 nM leukotriene D4 (LTD4) or 10 microM histamine. PMNLs spontaneously released thromboxane B2 (TXB2) during 60 min incubation, and the rate of formation was significantly reduced in the presence of 20 microM or 100 microM prednisolone. LTB4, LTC4, LTD4, and histamine stimulated the rate of TXB2 production during 1 min incubation to 93-, 49-, 60-, and 55-fold, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:14:38 GMT 2023
by
admin
on
Fri Dec 15 15:14:38 GMT 2023
|
Record UNII |
9PHQ9Y1OLM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QS03CA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS01CB02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QA01AC54
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S01CA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
D07CA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
C05AA04
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S01CB02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
A01AC54
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S02CA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QC05AA04
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 520.1880
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 520.2604
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QD07XA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QH02AB56
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS02BA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 524.1484K
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S01BB02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 520.2345H
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 524.1484F
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
NCI_THESAURUS |
C521
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
A07EA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QD07CA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
EQUISOLON (AUTHORISED)
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
V03AB05
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS01CA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S03BA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S01BA04
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QD07BA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 524.1445
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
R01AD52
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
H02AB06
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS03BA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS01BA04
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S02BA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
R01AD02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
D07AA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
D07BA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QR01AD52
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
21.2
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS02CA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.3
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QR01AD02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QD07AA03
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
S03CA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QV03AB05
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QH02AB06
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 520.2605
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-ATC |
D07XA02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QA07EA01
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
LIVERTOX |
794
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 522.1885
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
CFR |
21 CFR 524.1484J
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
||
|
WHO-VATC |
QS01BB02
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9900
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
2245
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
m9111
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | Merck Index | ||
|
PREDNISOLONE
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
5755
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
SUB10018MIG
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
PREDNISOLONE
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless. Solubility. Soluble in 1300 parts of water and in 30 parts of dehydrated ethanol R; soluble in methanol R and dioxan R. Category: Adrenocortical steroid. Storage: Prednisolone should be kept in a tightly closed container, protected from light. Additional information: Prednisolone is hygroscopic; it has a melting temperature of about 230?C with decomposition. Definition: Prednisolone contains not less than 97.0% and not more than 102.0% of C21H28O5, calculated with reference to thedried substance. | ||
|
8638
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | RxNorm | ||
|
9PHQ9Y1OLM
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
C769
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
1555005
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
DTXSID9021184
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
9PHQ9Y1OLM
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
3385
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
DB00860
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
535
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
100000091520
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL131
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
50-24-8
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
2866
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
D011239
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
8056-11-9
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
SUPERSEDED | |||
|
200-021-7
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
9120
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
Prednisolone
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY | |||
|
8378
Created by
admin on Fri Dec 15 15:14:38 GMT 2023 , Edited by admin on Fri Dec 15 15:14:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
BINDER->LIGAND |
BINDING LARGELY TO ALBUMIN; DOSAGE SHOULD BE REDUCED IN HYPOALBUMINANEMIA
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
||
|
PRODRUG -> METABOLITE ACTIVE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC PHARMACOKINETIC |
|
||